| Title |
Delafloxacin: design, development and potential place in therapy
|
|---|---|
| Published in |
Drug Design, Development and Therapy, March 2017
|
| DOI | 10.2147/dddt.s106071 |
| Pubmed ID | |
| Authors |
Francisco Javier Candel, Marina Peñuelas |
| Abstract |
Delafloxacin (DLX) is a new fluoroquinolone pending approval, which has shown a good in vitro and in vivo activity against major pathogens associated with skin and soft tissue infections and community-acquired respiratory tract infections. DLX also shows good activity against a broad spectrum of microorganisms, including those resistant to other fluoroquinolones, as methicillin-resistant Staphylococcus aureus. Its pharmacokinetic properties and excellent activity in acidic environments make DLX an alternative in the treatment of these and other infections. In this manuscript, a detailed analysis of this new fluoroquinolone is performed, from its chemical structure to its in vivo activity in recently published clinical trials. Its possible place in the current antimicrobial outlook and in other infectious models is also discussed. |
X Demographics
The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 33% |
| Unknown | 4 | 67% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 67% |
| Practitioners (doctors, other healthcare professionals) | 2 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 119 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 119 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 15 | 13% |
| Student > Bachelor | 13 | 11% |
| Student > Master | 12 | 10% |
| Student > Ph. D. Student | 11 | 9% |
| Other | 9 | 8% |
| Other | 15 | 13% |
| Unknown | 44 | 37% |
| Readers by discipline | Count | As % |
|---|---|---|
| Chemistry | 15 | 13% |
| Medicine and Dentistry | 13 | 11% |
| Biochemistry, Genetics and Molecular Biology | 11 | 9% |
| Agricultural and Biological Sciences | 8 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 5% |
| Other | 17 | 14% |
| Unknown | 49 | 41% |
Attention Score in Context
This research output has an Altmetric Attention Score of 17. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 June 2021.
All research outputs
#2,142,517
of 25,382,440 outputs
Outputs from Drug Design, Development and Therapy
#103
of 2,268 outputs
Outputs of similar age
#40,356
of 324,443 outputs
Outputs of similar age from Drug Design, Development and Therapy
#5
of 50 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,268 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 324,443 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 87% of its contemporaries.
We're also able to compare this research output to 50 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 90% of its contemporaries.